Long-term survival in small cell lung cancer: The case for a standard definition

Lung Cancer

Volumn 15, Issue 3, 1996, Pages 297-309

  Stephens, R J ^a   Bailey, A J ^a   Machin, D ^a   Thatcher, N ^a   Bleehen, N M ^a   Bolger, J J ^a   Clark, P I ^a   Connolly, C K ^a   Girling, D J ^a   Hasleton, P S ^a   Hopwood, P ^a   Macbeth, F R ^a   Moghissi, K ^a   Saunders, M I ^a   White, R J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

computer based literature search; cure; long term survivors; randomised clinical trials; small cell lung cancer

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; META ANALYSIS; PRIORITY JOURNAL; SURVIVAL;

EID: 0030298344     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(95)00594-3     Document Type: Article

References (27)

1. [1] Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stats Med 1995; 14: 2057-2079.
2. [2] Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of the bronchus: ten year follow-up. Lancet 1973; ii: 63-65.
3. [3] Medical Research Council Lung Cancer Working Party. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung: the results at 36 months. Br J Cancer 1981; 44: 611-617.
4. [4] Stephens RJ, Girling DJ, Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Lung Cancer 1994; 11: 259-274.
5. [5] Medical Research Council Lung Cancer Working Party. Cytotoxic chemotherapy before and after radiotherapy compared to radiotherapy followed by chemotherapy in the treatment of small-cell carcinoma of the lung: the results at 36 months. Br J Cancer 1984; 48: 755-761.
6. [6] Medical Research Council Lung Cancer Working Party. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Respir Med 1989; 83: 51-58.
7. [7] Medical Research Council Lung Cancer Working Party. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989; 59: 584-590.
8. [8] Medical Research Council Lung Cancer Working Party. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: Survival and prognostic factors. Br J Cancer 1993; 68: 1150-1156.
9. [9] Medical Research Council Lung Cancer Working Party. Randomised trial of four-drug versus less intensive two-drug chemotherapy in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996; 73: 406-413.
10. [10] COMPACT Steering Committee: Improving the quality of clinical trials in cancer. Br J Cancer 1991; 63: 412-415.
11. [11] Parmar MKB, Machin D. Survival Analysis: a Practical Approach. Wiley, Chichester, UK, 1995.
12. [12] OPCS Mortality Statistics: cause. DH2 No. 20. HMSO London 1993.
13. [13] BMDP. BMDP Statistical Software Manual. Berkeley, CA: University of California Press, 1988.
14. [14] SAS. SAS Institute Inc, Cary, NC, 1989.
15. [15] SPSS. SPSS-X User's Guide, 3rd edn. SPSS: Chicago, IL, 1988.
16. [16] Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990; 61: 584-589.
17. [17] Rosti G, Seagliotti G, Crino L, Ardizzoni A, De Lena M, Capitolo S, Marangolo M. Second cancers as late complications in small cell lung cancer (SCLC) long term survivors. Lung Cancer 1991; 7 (Suppl); 180, 668.
18. [18] Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell cancer (SCLC): The role of sex as a predictor for survival. Br J Cancer 1991; 63: 986-992.
19. [19] Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 6: 597-604.
20. [20] Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46: 4189-4194.
21. [21] Begg CB, Berlin JA. Publication bias and disseminating clinical research. J Natl Cancer Inst 1989; 81: 107-115.
22. [22] Armstrong JG. Long-term outcome of small cell lung cancer. Cancer Treat Rev 1990; 17:1-13.
23. [23] Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1714 consecutive patients. J Clin Oncol 1995; 13: 1215-1220.
24. [24] Heyne KH, Lippman SM, Lee JJ, Lee JS, Waun Ki Hong. The incidence of second primary tumours in long term survivors of small cell lung cancer. J Clin Oncol 1992; 10: 1519-1524.
25. [25] Belani CP, Whitacre M, Aisner J. Redefinition of outcome of long-term survivors with small cell lung cancer. Pro Annu Meet Am Soc Clin Oncol 1994; 13: 329 (abstract) A1088.
26. [26] Jones DR, Powles RL, Machin D, Sylvester RJ. On estimating the proportion of cured patients in clinical studies. Biometrie Praximetrie 1981; 21: 1-11.
27. [27] Maller RA, Zhou S. Testing for the presence of immune or cured individuals in censored survival data. Biometrics 1995; 51: 1197-1205.